Donald F Brophy

Summary

Affiliation: Virginia Commonwealth University
Country: USA

Publications

  1. ncbi Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients
    D F Brophy
    Coagulation Special Studies Laboratory, Department of Pharmacy of Virginia Commonwealth University, Richmond, VA 23298, USA
    Haemophilia 13:533-41. 2007
  2. doi A pilot study of genetic polymorphisms and hemodialysis vascular access thrombosis
    Donald F Brophy
    Department of Pharmacy, Virginia Commonwealth University, Richmond, 23298 0533, USA
    Hemodial Int 13:19-26. 2009
  3. ncbi Use of enoxaparin in patients with chronic kidney disease: safety considerations
    Donald F Brophy
    Department of Pharmacy, Virginia Commonwealth University Medical College of Virginia Campus, Richmond, Virginia 23298 0533, USA
    Drug Saf 30:991-4. 2007
  4. doi Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A
    Donald F Brophy
    School of Pharmacy, Coagulation Advancement Laboratory, Virginia Commonwealth University, Richmond, VA, USA
    Blood Coagul Fibrinolysis 21:539-46. 2010
  5. ncbi The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients
    Donald F Brophy
    Department of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298 0533, USA
    Thromb Res 119:723-9. 2007
  6. ncbi Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease
    D F Brophy
    Department of Pharmacy Practice, Virginia Commonwealth University Medical College of Virginia, Richmond, VA 23298, USA
    J Thromb Haemost 4:372-6. 2006
  7. ncbi Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis
    Donald F Brophy
    School of Pharmacy, Virginia Commonwealth University Medical College of Virginia VCU MCV, Richmond, VA 23298 0533, USA
    Ann Pharmacother 39:1808-11. 2005
  8. doi Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy
    Donald F Brophy
    Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA
    Ann Pharmacother 44:43-9. 2010
  9. doi Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h
    D F Brophy
    Coagulation Advancement Laboratory, Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University VCU, Richmond, VA, USA
    Haemophilia 17:e949-57. 2011
  10. ncbi Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time
    Donald F Brophy
    Department of Pharmacy Practice, Virginia Commonwealth University Medical College of Virginia, Richmond, VA, USA
    Am J Kidney Dis 44:270-7. 2004

Collaborators

Detail Information

Publications27

  1. ncbi Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients
    D F Brophy
    Coagulation Special Studies Laboratory, Department of Pharmacy of Virginia Commonwealth University, Richmond, VA 23298, USA
    Haemophilia 13:533-41. 2007
    ..NN1731 may be a promising haemostatic agent for patients with bleeding disorders. These results should be confirmed in an in vivo study...
  2. doi A pilot study of genetic polymorphisms and hemodialysis vascular access thrombosis
    Donald F Brophy
    Department of Pharmacy, Virginia Commonwealth University, Richmond, 23298 0533, USA
    Hemodial Int 13:19-26. 2009
    ..The NOS3 420 bp allele may have an association with thrombosis; however, further epidemiologic data evaluating large dialysis registries are needed to confirm our observation...
  3. ncbi Use of enoxaparin in patients with chronic kidney disease: safety considerations
    Donald F Brophy
    Department of Pharmacy, Virginia Commonwealth University Medical College of Virginia Campus, Richmond, Virginia 23298 0533, USA
    Drug Saf 30:991-4. 2007
  4. doi Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A
    Donald F Brophy
    School of Pharmacy, Coagulation Advancement Laboratory, Virginia Commonwealth University, Richmond, VA, USA
    Blood Coagul Fibrinolysis 21:539-46. 2010
    ..HAS and TEG assays provided similar estimates of FOT and R, however CEM appeared to be more sensitive than MA to changes in clot firmness...
  5. ncbi The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients
    Donald F Brophy
    Department of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298 0533, USA
    Thromb Res 119:723-9. 2007
    ....
  6. ncbi Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease
    D F Brophy
    Department of Pharmacy Practice, Virginia Commonwealth University Medical College of Virginia, Richmond, VA 23298, USA
    J Thromb Haemost 4:372-6. 2006
    ..This phenomenon appears to occur despite judicious monitoring of antifactor Xa (aFXa) activity. Better monitoring parameters are needed to quantify the anticoagulant effects of enoxaparin in the ESRD population...
  7. ncbi Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis
    Donald F Brophy
    School of Pharmacy, Virginia Commonwealth University Medical College of Virginia VCU MCV, Richmond, VA 23298 0533, USA
    Ann Pharmacother 39:1808-11. 2005
    ..These medications improve patient outcomes and quality of life. Their costs, however, remain a major barrier for health systems...
  8. doi Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy
    Donald F Brophy
    Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA
    Ann Pharmacother 44:43-9. 2010
    ..Studies have found that hemoglobin concentrations are often low among dialysis patients after hospital discharge, yet little is known about inpatient anemia treatment...
  9. doi Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h
    D F Brophy
    Coagulation Advancement Laboratory, Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University VCU, Richmond, VA, USA
    Haemophilia 17:e949-57. 2011
    ..The PCF and CEM were correlated to FVII:C and characterized the dynamics of platelet function and clot strength over the rFVIIa dosing interval. The clinical significance of these findings needs additional study...
  10. ncbi Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time
    Donald F Brophy
    Department of Pharmacy Practice, Virginia Commonwealth University Medical College of Virginia, Richmond, VA, USA
    Am J Kidney Dis 44:270-7. 2004
    ....
  11. ncbi Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease
    Donald F Brophy
    Department of Pharmacy, Virginia Commonwealth University Medical College of Virginia School of Pharmacy, Richmond, Virginia 23298 0533, USA
    Expert Opin Pharmacother 4:1461-9. 2003
    ..This review details these important pharmacoeconomic considerations...
  12. doi Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays
    Donald F Brophy
    Coagulation Advancement Laboratory, Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA
    Blood Coagul Fibrinolysis 22:541-6. 2011
    ..28 μg/ml. Vatreptacog alfa produced more pronounced coagulation effects at lower concentrations than rFVIIa; and the 0.56 μg/ml concentration completely normalized responses in all patients...
  13. ncbi Role of N-acetylcysteine in the prevention of radiocontrast-induced nephropathy
    Donald F Brophy
    Department of Pharmacy, Virginia Commonwealth University Medical College of Virginia School of Pharmacy, PO Box 980533, Richmond, VA 23298 0533, USA
    Ann Pharmacother 36:1466-70. 2002
    ..To examine the role of N-acetylcysteine (NAC) in the prevention of radiocontrast-induced nephropathy (RIN)...
  14. ncbi The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies
    Donald F Brophy
    Department of Pharmacy, Coagulation Special Studies Laboratory, Virginia Commonwealth University Medical College of Virginia VCU MCV, Richmond, Virginia, USA
    J Clin Pharmacol 46:887-94. 2006
    ..Therefore, these subjects exhibit greater thrombin generation time prolongation despite similar antifactor Xa exposure. Further large-scale studies are needed to corroborate the results of this exploratory pilot study...
  15. doi Examining platelet-fibrin interactions during traumatic shock in a swine model using platelet contractile force and clot elastic modulus
    Nathan J White
    Reanimation Engineering Science Center, Department of Emergency Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    Blood Coagul Fibrinolysis 22:379-87. 2011
    ....
  16. pmc Systemic central venous oxygen saturation is associated with clot strength during traumatic hemorrhagic shock: A preclinical observational model
    Nathan J White
    Reanimation Engineering Science Center, Virginia Commonwealth University, Richmond, 23298, USA
    Scand J Trauma Resusc Emerg Med 18:64. 2010
    ..We hypothesize that oxygen transport measurements will be associated with clot strength during traumatic shock, and test this hypothesis using a swine model of controlled traumatic shock...
  17. pmc Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids
    Brian L Henry
    Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia, USA
    Blood Coagul Fibrinolysis 20:27-34. 2009
    ..These results demonstrate that sulfated DHPs possess good in-vitro and ex-vivo activity, which will likely be improved through a rational design...
  18. doi Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients
    Gretchen M Brophy
    Departments of Pharmacotherapy and Outcomes Sciences and Neurosurgery, Virginia Commonwealth University School of Pharmacy, P O Box 980533, 410 N 12th Street, Richmond, VA 23298, USA
    Neurocrit Care 13:176-81. 2010
    ..There is a paucity of studies comparing stress ulcer prophylaxis (SUP) agents in high-risk neurosurgical patients...
  19. ncbi Automated peritoneal dialysis: new implications for pharmacists
    D F Brophy
    Virginia Commonwealth University School of Pharmacy, Medical College of Virginia, Richmond 23298, USA
    Ann Pharmacother 31:756-64. 1997
    ..To review the new automated peritoneal dialysis (APD) modalities that are available to patients with end-stage renal disease (ESRD), and to examine their potential pharmacokinetic and drug dosing consequences...
  20. ncbi Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction
    D F Brophy
    Department of Pharmacy, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia, USA
    J Thromb Haemost 2:1299-304. 2004
    ..These results suggest that patients with renal dysfunction have a greater pharmacodynamic response to LMWH, independent of the pharmacokinetics of LMWH...
  21. ncbi Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia
    L D Wazny
    Internal Medicine Nephrology, School of Pharmacy, Virginia Commonwealth University, Richmond 23298, USA
    Ann Pharmacother 34:94-7. 2000
    ..To review the published clinical data assessing the role of amiloride in the prevention of amphotericin B (AmB)induced electrolyte disorders...
  22. pmc Coagulopathy and traumatic shock: characterizing hemostatic function during the critical period prior to fluid resuscitation
    Nathan J White
    Department of Emergency Medicine, Virginia Commonwealth University, AD Williams Clinic 2nd Floor, Room 242, 1201 East Marshall Street, Richmond, VA 23298, USA
    Resuscitation 81:111-6. 2010
    ..A combat-relevant swine model was used to investigate the development of coagulopathy during trauma by monitoring hemostatic function during increasing severity of shock...
  23. ncbi Development of an efficient sampling strategy to predict enoxaparin pharmacokinetics in stage 5 chronic kidney disease
    Brian R Overholser
    Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University, Indianapolis and West Lafayette, Indiana 46202, USA
    Ther Drug Monit 28:807-12. 2006
    ..This sampling strategy may be used for therapeutic drug monitoring of enoxaparin and for future clinical trials in patients with chronic kidney disease...
  24. ncbi Venous thromboembolism prevention in acutely ill nonsurgical patients
    Donald F Brophy
    School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA
    Ann Pharmacother 39:1318-24. 2005
    ..To review recent advances in the prevention of venous thromboembolism (VTE) in acutely ill nonsurgical inpatients...
  25. ncbi Attenuation of Sepsis-induced Organ Injury in Mice by Vitamin C
    Bernard J Fisher
    Division of Pulmonary Disease and Critical Care Medicine, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    JPEN J Parenter Enteral Nutr . 2013
    ..VitC sufficiency or parenteral infusion of VitC, following induction of sepsis, normalized physiological functions that attenuated the development of MODS in sepsis...
  26. ncbi The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease
    D F Brophy
    Department of Primary Care, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia 23249, USA
    Pharmacotherapy 21:169-74. 2001
    ..CONCLUSIONS: Based on antifactor Xa activity, ESRD has little effect on the pharmacokinetics of enoxaparin, and dosing adjustments are unnecessary...
  27. doi Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings
    Jerry Siegel
    College of Pharmacy, The Ohio State University Medical Center, Columbus 43210, USA
    Am J Health Syst Pharm 65:1711-9. 2008
    ..Erythropoiesis-stimulating agent (ESA) use in the outpatient and inpatient settings through pharmacist-conducted, hospital-based chart audits is examined and discussed...